A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
New England Journal of Medicine2006Vol. 354(9), pp. 899–910
Citations Over TimeTop 1% of 2006 papers
Chris H. Polman, Paul O’Connor, Eva Havrdová, Michael Hutchinson, Ludwig Kappos, David H. Miller, J. Theodore Phillips, Fred Lublin, Gavin Giovannoni, A Wajgt, Martin Toal, Frances Lynn, Michael Panzara, Alfred Sandrock
Abstract
Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis. Adhesion-molecule inhibitors hold promise as an effective treatment for relapsing multiple sclerosis. (ClinicalTrials.gov number, NCT00027300.).
Related Papers
- → Characterizing the ‘feel-good experience’ in Multiple Sclerosis Patients Treated With Natalizumab Or Other Therapies(2022)7 cited
- → Severe relapses after the first infusion of natalizumab in active relapsing—remitting multiple sclerosis(2009)13 cited
- → Early relapses after the first dose of natalizumab in active multiple sclerosis patients(2008)10 cited
- → Corrigendum to “Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation” [Multiple Sclerosis and Related Disorders 38 (2020) 101498](2020)1 cited
- → Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?(2014)4 cited